Cost-effectiveness with PCSK9 inhibitors: a matter of costs

European Heart Journal - Cardiovascular Pharmacotherapy

5 January 2018

Organised by:

Read full article

Contributors

Heinz Drexel

Heinz Drexel

Author

Vorarlberg Institute for Vascular Investigation and Treatment Feldkirch , Austria

You may be interested in

Congress Presentation

Cost impact of the ESC/EAS 2019 dyslipidemia guidelines recommended use of PSCK9i in very-high-risk patients with an LDL <1.8mmol/L for secondary prevention

26 August 2023

Congress Presentation

Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials

3 September 2019

Congress Presentation

Review on clinical strategies for managing patients with elevated Lp(a): Cost-effectiveness of Lp(a) testing and awareness of lifestyle changes via Public Health Policy in absence of targeted therapy

24 June 2023

Webinar

Injectable therapies for cardiovascular disease: optimising their use in practice - experiences from the UK and Italy

18 March 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources